INSTITUTIONALISING SCHISTOSOMIASIS SURVEILLANCE: BEST PRACTICES TO IMPROVE FEMALE GENITAL AND URINARY SCHISTOSOMIASIS CONTROL IN SOUTH AFRICA

Takalani Girly Nemungadi, Tsakani Furumele, Absalom Mwazha, Myra Taylor, Saloshni Naidoo, Eyrun F. Kjetland
doi: https://doi.org/10.1101/2024.10.21.24315852

ABSTRACT

Background In the absence of an active schistosomiasis control program, the affected community is vulnerable to complications such as female genital schistosomiasis. Research has shown that female genital schistosomiasis is a challenge faced by many African women including those from South Africa. Since 2008, the South African National Department of Health has been trying to resuscitate the schistosomiasis control programme; the programme has not been fully established or implemented. However, there are some surveillance best practices that the country can institutionalise to improve control.

Materials and methods A descriptive analysis of schistosomiasis data from the National Health Laboratory Services, Notifiable Medical Conditions Surveillance System, and District Health Information System was conducted in 2023. A document review was also carried out in 2023 to determine surveillance best practices to guide the establishment of sentinel sites for improving schistosomiasis and female genital schistosomiasis control.

Results The Health Laboratory Services, Notifiable Medical Conditions Surveillance System, and District Health Information System are the existing surveillance and reporting systems. According to Notifiable Medical Conditions Surveillance System (the overall and central notification system for the notifiable medical conditions), a total of 56529 schistosomiasis cases were reported nationwide between 2017 and 2021 (ranging from annual cases of 4140 to 15032). The majority of cases (>90%) were reported from public health facilities. The country’s regulations on the surveillance and control of notifiable medical conditions stipulate that schistosomiasis is one of the priority conditions that should be notified (within 7 days of clinical or laboratory diagnosis) by all public and private health care providers, as well as public and private health laboratories. The regulations did not specify female genital schistosomiasis as one of the notifiable medical conditions. As a result, there was no reported data on female genital schistosomiasis.

Conclusion The data collected through the National Health Laboratory Services, Notifiable Medical Conditions Surveillance System, and District Health Information System demonstrate that there are formalised schistosomiasis reporting systems, but no female genital schistosomiasis reporting. The existence and use of these surveillance systems demonstrate the country’s potential to integrate the systems to enhance the prevention, surveillance, reporting, and management of schistosomiasis and introduction of surveillance for female genital schistosomiasis surveillance. Prioritisation of schistosomiasis and female genital schistosomiasis surveillance is paramount and will generate valuable information that will guide the review and implementation of the current and old policies that were developed by the National Department of Health and stakeholders.

INTRODUCTION

Schistosomiasis is a neglected tropical disease that primarily affects impoverished communities in tropical Africa, the Middle East, Asia, Brazil, and South America that lack access to potable water and proper sanitation (1–10). There is currently no vaccine for schistosomiasis, and current control strategies rely heavily on praziquantel treatment through mass drug administration for school-aged children (1,11,12). Treatment with praziquantel is effective against the adult worm but has no effect on the presence of ova or migrating schistosomula to adults and the resultant patency (1,13–16). Treatment alone will not keep the infection from recurring and, as a result, several rounds of treatment and discontinued exposure to risky water contact may be required for effectiveness (17). Providing safe water to affected communities is critical to prevent re-infection following treatment. If left untreated, schistosomiasis can lead to complications which include the onset of female genital schistosomiasis (FGS) which presents in different morphologic subtypes (grainy sandy patches and homogenous yellow patches at 15 times magnification, abnormal blood vessels, and rubbery papules) (6,18,19).

It has been reported that sub-Saharan Africa accounts for only about 13% of the global population and that sub-Saharan Africa accounts for up to 90% of schistosomiasis cases and an estimated 280,000 deaths each year (1,11,12). Schistosomiasis is endemic in the northern and eastern parts of South Africa, with S. haematobium being the most common species, and requires an active control programme (20). Even though several countries have not achieved the WHO-recommended schistosomiasis preventive chemotherapy (PC) target of 75% of school-aged children, they have long implemented their programme in comparison to South Africa which is still struggling to implement the control programme and PC in the affected provinces and districts (1,12,21,22).

In the absence of an active control program, the affected communities are vulnerable to complications such as FGS (18,19). The last active control programme in South Africa was implemented in KwaZulu-Natal between 1997 and 2000 (23,24). Understanding the country’s schistosomiasis situation, followed by monitoring progress towards the World Health Organisation (WHO) specified elimination target of <1% proportion of heavy intensity infections is key to a successful control programme (11). There is currently no program data on infection intensity in South Africa, except as determined by some studies in the KwaZulu-Natal Province (25–28).

South Africa has still not accepted the WHO-donated medication for schistosomiasis because the drug is not registered in the country, and treatment is currently case-based (29,30). Consequently, only those seeking medical attention would be treated, while others might dismiss the symptoms of genital discharge or dysuria as normal and live with these (31). Currently, urine or stool specimens are collected from all suspected schistosomiasis cases seen in health facilities for laboratory confirmation (32). However, laboratory data is not often published and is not being used to the greatest extent possible to inform policy, and those infected who do not seek medical attention will remain infected either silently or with symptoms they believe are normal.

The establishment of sentinel sites is one of the recommended common and best practices that provide opportunities for improving surveillance systems (33). If integrated with cervical cancer screening and other reproductive health services, these sentinel sites can facilitate the establishment of baseline prevalence of FGS through FGS screening and case management, as well as regular monitoring and evaluation surveys every 3 or 5 years are also appropriate for monitoring control progress (33). In this paper, we explored secondary schistosomiasis data and conducted a review of all available documents to identify surveillance best practices that can be institutionalized to improve and integrate schistosomiasis and FGS surveillance, prevention and control.

MATERIAL AND METHODS

Ethical considerations

The study was approved by the Biomedical Research Ethics Committee (BREC), University of KwaZulu-Natal (Ref BF029/07), KwaZulu-Natal Department of Health (Reference HRKM010-08) and the Regional Committee for Medical and Health Research Ethics (REC), South Eastern Norway (Ref 46907066a1.2007.535). Approval was granted from the National Department of Health to utilise data from the District Health Information System (DHIS) and from both the National Department of Health (NDOH) and the National Institute for Communicable Diseases to utilise data from the Notifiable Medical Conditions Surveillance System (NMCSS). Approval was granted from the National Health Laboratory Services (NHLS) to utilise data from the NHLS system.

Study design, subjects and area

The study was conducted in South Africa.

Descriptive study design

The study focused on analysis of secondary data from the NHLS (National Health Laboratory Services) for the period 2014 - 2018, secondary data from the NMCSS (Notifiable Medical Conditions Surveillance System) of the NICD (National Institute for Communicable Diseases) for the period 2017 - 2021, and secondary data from the DHIS (District Health Information System) of the NDOH (National Department of Health) for the period 2017 - 2021. The data is of patients who visited health facilities in South Africa and were suspected of having schistosomiasis based on urological symptoms. The flow of data is shown in Figure 1.

Figure 1.
Figure 1.

Flow diagram for the schistosomiasis data reporting in South Africa DHIS - District Health Information System; NHLS - National Health Laboratory Services; NMCSS - Notifiable Medical Conditions Surveillance System.

Document review

All national documents on schistosomiasis surveillance and control were obtained from the National Department of Health. All the documents were reviewed through reading and extraction of surveillance recommended actions for schistosomiasis and FGS, to identify surveillance opportunities and best practices that can be institutionalised to improve disease control. The focus was on the documents from the National Department of Health, only because they provide overall national guidance.

Data sources, collection, processing, and analysis

There were three main sources of data, namely: the NHLS, the NMCSS, the DHIS, and previously published research data. The NHLS, NMCSS, and DHIS schistosomiasis data are reported from all nine provinces of South Africa; these three systems do not report on FGS. The NHLS and DHIS are electronic systems that collect data from patients who visit public health facilities, whereas the NMCSS is an electronic system that collects data from both public and private health facilities (including the NHLS data). As a result, the number of cases reported on the NMCSS is greater than the number of cases reported on the NHLS. The NMCSS is the primary reporting system for all notifiable medical conditions, including schistosomiasis, whereas the DHIS is a parallel system (34).

Nation-wide laboratory data for patients tested for urinary schistosomiasis and patients confirmed positive for urinary schistosomiasis, for the period 2014 – 2018, was obtained from the NHLS. Nation-wide data for patients confirmed by laboratory to have urinary schistosomiasis, for the period 2017 – 2021, was obtained from the NICD NMCSS. Nation-wide aggregated data for urinary schistosomiasis cases reported to the DHIS, for the period 2017 – 2021, was obtained from the National Department of Health.

All data was received in Excel Spreadsheets. The NHLS data were received with the following variables: episode number, ward name, facility name, facility type, facility classification, sub-district name, district name, province name, taken date, tested date, age tested in years, sex, specimen type, testing lab, erythrocytes, Schistosoma haematobium ova (observed denoted as OBS or OBSV, and not observed denoted as NOBS), schistosomiasis results. The NHLS data was cleaned, re-coded, and the recordings “OBS, NOBS and OBSV” were standardised as “OBS” to indicate the presence of schistosoma eggs and “NOBS” to indicate the absence of schistosoma eggs.

The NMCSS dada was received with the following variables: condition,, case classification, Notifiable Medical Condition (NMC) Facility, Sub District, District, Province, notifier, date symptoms, date diagnosis, notification date, folder number, patient first name, patient surname, gender, pregnancy status, date of birth, age in years, age category, citizenship, residential country, residential province, residential suburb, residential city town, travel history, travel1 country, travel1 province, travel1 city town, date travel1 from, date travel1 to, travel2 country, travel2 province, travel2 city town, date travel2 from, date travel2 to, symptom1, symptom2, treatment1, treatment2, vaccination status, date last vaccination, contact history, diagnosis method, specimen taken, specimen1 barcode, date specimen1 taken, patient status, date patient death, patient admission status, episode no. The NMCSS data was reviewed for errors and missing data using MS Excel filter and sorting, and duplicates using MS Excel Conditional Formatting.

The DHIS data was received with the following variables: province, district and year

The analysis was done using the Excel. The positivity rates and prevalence of urinary schistosomiasis cases per year per district and province were determined using basic descriptive statistics (frequency and prevalence). The DHIS aggregated data was reported as received. The World Health Organisation endemicity measures were used to categorise districts, by using the calculated positivity rates from NHLS data, as low (<10%), moderate (≥10% but <50%), and high risk (≥50%).

We defined an active control programme as a programme that fully implements the control activities as recommended by the World Health Organisation, namely: mass drug administration through prevention chemotherapy; water, sanitation and hygiene (WASH) activities; vector control; case-by-case management; surveillance; and other primary prevention measures to promote behavioural change, self-care and environmental management interventions (11). All the schistosomiasis and related documents were obtained from the National Department of Health Directorate: Communicable Diseases Control, as it is expected to coordinate the implementation of the schistosomiasis control programme (35). These documents were reviewed to identify the existing policy and guidance in schistosomiasis and FGS surveillance and how they are being implemented.

Data from the NHLS, the NMCSS, and the DHIS were compared to previously published research data to see if there were any correlations in prevalence.

RESULTS

Surveillance best practices and gaps

Although the country’s schistosomiasis control programme is not active, efforts are made to develop guidelines and policies to guide implementation (Table 1). The following surveillance activities were found to be recommended in the National Neglected Tropical Diseases (NTD) Master Plan, and they were directly quoted:

View this table:
Table 1. Best practices identified during document review, for schistosomiasis and FGS control in South Africa
View this table:
Table 2. Gaps identified during document review, for schistosomiasis and FGS control in South Africa

“Establish sentinel sites in selected communities and schools”. “Introduce NTD surveillance data management within an integrated platform to ensure data flow is automated and available in real-time”. “Develop surveillance guidelines and data management tools for NTDs”. “Create cross border activities to strengthen surveillance between neighbouring countries and provinces”. “Impact assessment surveys for Soil-transmitted Helminths and Schistosomiasis every 3 years and validation of data”. “To carry out pharmacovigilance of NTD drugs including drug resistance surveillance”.

“Conduct baseline surveys”. “Production and distribution of NTD Surveillance information, education and communication (IEC) materials in local languages”. “Develop Surveillance IEC materials”.

Laboratory data and analysis

According to NHLS data, a total of 35,232 patients were suspected of having schistosomiasis between 2017 and 2018, with a urinary microscopy positivity rate of 10.4% (n=3653). For the period 2014 to 2018, the positivity rate ranged from 0% to 36%, with Limpopo Province reporting the highest positivity rate, followed by Mpumalanga and KwaZulu-Natal (Table 3). In 2015, the North West Province reported a higher prevalence of 12% as compared to other reporting periods. Data analysis by district showed that although the number of patients tested in some districts was low, at least one district in each of the nine provinces reported a positivity rate of more than 10% (Appendix 1). The majority of the districts had a positivity rate greater than 10% but less than 50% (moderate prevalence). The districts that had a positivity rate of ≥50% (high risk) included Amathole District in 2015 and 2016 in the Eastern Cape Province, Mopani District in 2017 in Limpopo Province, OR Tambo District in 2014 in Eastern Cape Province, and Vhembe District in 2017 in Limpopo Province. West Coast District also reported a positivity rate of more than 50% in 2015, but only two patients were tested. The positivity rate dropped from 12.6% in 2017 to 10.8 in 2018; however, due to inconsistent reporting, it was difficult to determine whether this was a true decrease.

View this table:
Table 3. Clinically diagnosed schistosomiasis in 9 provinces and urinary microscopy positivity rate, National Health Laboratory Services, South Africa, 2014 – 2018

Data from the NMCSS system demonstrate that schistosomiasis cases are reported every year in South Africa, in both public and private health facilities (Figure 2). Of the total of 56,529 cases reported, the majority were laboratory-confirmed, but 20 cases were diagnosed by signs and/or symptoms only, and 12 cases had no diagnosis. The total number of cases reported through the NMCSS in the country increased during 2017-2019 (N=8823 in 2017, N=14960 in 2018, N=15032 in 2019), and decreased during the COVID-19 pandemic (N=13574 in 2020, and N=4140 in 2021). Over the five years, 2017-2022, most of the cases were reported from KwaZulu-Natal Province (N=20315 (36%) and over 5,000 cases reported each year in 2018 and 2019), followed by Limpopo Province (N=17001, 30%), Mpumalanga (N=11045, 20%) and Eastern Cape (N=4826, 9%). None of these were investigated for FGS.

Figure 2.
Figure 2.

Schistosomiasis per year, NMCSS, South Africa, 2017 – 2021

According to the NMCSS data, all districts in the three most affected provinces (KwaZulu-Natal, Limpopo and Mpumalanga) reported cases of schistosomiasis. Ehlanzeni District in Mpumalanga Province reported the highest cases as compared to other districts (N=1462 in 2017, N= 2735 in 2018, N=2780 in 2019, N=2473 in 2020 and N=714 in 2021), followed by Vhembe District in Limpopo Province (Figure 3).

Figure 3.
Figure 3.

District trends of schistosomiasis per year, NMCSS, South Africa, 2017 – 2021

For the period 2017 – 2021, more males (N=40172; 71%) tested positive for schistosomiasis as compared to females (N=14456; 26%) (Figure 4).

Figure 4.
Figure 4.

Annual schistosomiasis cases by gender, NMCSS, South Africa, 2017 - 2021

Most cases were reported among the age group 10-14 years (>30% of the positive cases were found in this age group, each year during 2017-2021), followed by the age group 15-19 years (>19%) (Figure 5). Other age groups that were frequently affected were 5-9 years (between 12% and 16% of the positive cases were found in this age group each year), and 20-24 (between 9% and 11%).

Figure 5.
Figure 5.

Schistosomiasis positive by age category, NMCSS, South Africa, 2017 – 2021

As shown in Figure 6, since 2017, the DHIS surveillance system has reported fluctuating numbers of schistosomiasis cases. Similar to the data reported through the NMCSS, over the five years (2017-2021), KwaZulu-Natal contributed the most cases followed by Limpopo and Mpumalanga (Western Cape did not report any cases).

Figure 6.
Figure 6.

Schistosomiasis cases reported through DHIS, South Africa, 2017 – 2021

The analysis of DHIS data by district showed that within the known endemic provinces, Vhembe district in Limpopo reported the majority of cases for the period 2017 to 2021, followed by Mopani district in Limpopo and Ehlanzeni district in Mpumalanga.

DISCUSSION AND CONCLUSION

The findings suggest that South Africa has surveillance best practices that offer opportunities for the country to improve schistosomiasis and FGS prevention and management because schistosomiasis is notified through the three systems. Data from the three systems is similar to the data reported by previous research and the mapping exercise conducted by NDoH in terms of the provinces that report the most cases and the most affected age groups (25–28,44–46). The reported data are also very similar to data reported by other countries, indicating that the data may be reasonably reliable despite the selection.

Although the NMCSS and the NHLS systems are integrated, the DHIS was found to be independent of these two surveillance systems. The NHLS and DHIS are accessible by all public health facilities whereas the NMCSS is accessible by both public and private healthcare facilities and laboratories; there is therefore a need for an integrated surveillance system to maximize output and efficiency. The existence of regulations relating to notifiable medical conditions provides opportunities for improvement in reporting and reporting standards (including data quality improvements) as all public and private laboratories are expected to comply with these regulations and notify all priority medical conditions including schistosomiasis. However, FGS still needs to be indicated as one of the priority medical conditions to facilitate the establishment of its surveillance, and to facilitate public and private laboratory and healthcare facility compliance in reporting diagnosis (34).

South Africa has a sizable population (27%) that relies on the private health sector for medical care (47), and according to the NMCSS, these communities are also prone to schistosomiasis infection. As a result, capacity building and enforcement of the Regulations relating to surveillance and control of notifiable medical conditions would ensure that public and private health sectors comply with reporting and assist the country in better understanding the disease burden to inform control measures.

The Laboratory capacity also provides opportunities for operationalising the sentinel sites proposed by Nemungadi et al (33), capacitated through clinician and other health worker training, as well as the provision of equipment and tools for screening for schistosomiasis and FGS, treatment of at-risk community members, data management, and reporting. The mapping exercise data and the previously published schistosomiasis and FGS research data support the need for establishing sentinel sites to better understand disease burden (25–28,44–46). Operationalisation of these sentinel sites may assist the country in establishing the FGS baseline prevalence, confirming the schistosomiasis prevalence data from published research and from the mapping exercise conducted between 2016 and 2019 (33). The overall program will enable the country to implement a monitoring and evaluation program and track progress toward WHO schistosomiasis elimination targets, with monitoring indicators related to baseline schistosomiasis and FGS prevalence, quarterly and annual case detection rate for schistosomiasis and FGS, cases of local origin and those that are imported, the population at risk, and treatment coverage. For the sentinel sites to be successful, dedicated staff and supportive supervisory visits will be key.

The availability of praziquantel for case-based treatment in all health facilities demonstrates some country’s capacity to manage schistosomiasis cases. However, case-based treatment for schistosomiasis has its own set of challenges due to low treatment demand and poor health-seeking behaviour among most affected people (31). As a result, a large number of community members remain untreated and probably have FGS complications and continue to shed eggs and potentially contaminate water bodies. Annual testing and the positivity rate are very low when compared with the population size and research conducted in the past in KwaZulu-Natal, Limpopo and Mpumalanga provinces. The age tested also reveals that the majority of young females (below 16 years) may be missing the schistosomiasis and FGS treatment benefits and consequently are at high risk of FGS due to lack of mass drug administration and a FGS control programme, as well as the social difficulties of these young females in accessing gynaecological investigations. In this context, sentinel sites may be a better option to target hot spots and conduct targeted mass drug administration to prevent schistosomiasis complications from FGS; this option may be cheaper than a blanket mass drug administration using the currently registered praziquantel. At the sentinel sites, schistosomiasis testing and FGS screening could be improved by routinely selecting and screening community members who visit healthcare facilities in affected or at-risk areas, based on a history of exposure. As a result, the demand for treatment will increase and it would put the country at an advantage in demonstrating the cost-effectiveness of mass drug administration and motivating the availability of WHO-donated medication.

The lack of sustainability in meetings and communication through the Neglected Tropical Diseases Task Team and the lack of FGS as one of the main agenda items necessitates the need for awareness about FGS among stakeholders including programme managers, clinicians and community members. A successful schistosomiasis control program demands multi-stakeholder and multi-sectoral collaboration. The interest of some academic institutions in schistosomiasis research, such as the University of KwaZulu-Natal and the University of Venda, provides an opportunity for the country to involve stakeholders in managing and controlling the disease, as well as FGS as a complication. The NICD Centre for Emerging Zoonotic and Parasitic Diseases, as well as other government agencies like Water and Sanitation and Local Municipalities, would provide excellent opportunities for improving operational research and public health. Academic and research institutions bring research skills that can help with program monitoring and evaluation. Schistosomiasis has been linked to increased HIV transmission, and some FGS cases have been misdiagnosed as STIs (4,13). As a result, to maximize effectiveness and efficiency, the schistosomiasis control program could be integrated with the HIV, STI, and reproductive health programs.

The National Department of Health’s mapping of schistosomiasis in all nine provinces of South Africa demonstrates that the country has some capacity to implement the schistosomiasis and FGS control program. As a follow-up of the mapping findings, the WHO treatment strategy and other prevention and control measures need to be implemented in all at-risk communities. The country needs to prioritise implementation of the Neglected Tropical Diseases Master Plan and the Coordination Mechanism and develop a monitoring and evaluation plan. The WHO FGS pocket atlas for clinical healthcare professionals is a good resource for training clinicians on FGS screening and management (19).

Limitations to the findings include the fact that only data from the existing surveillance system and a review of the existing documents were considered instead of involving the qualitative component of interviewing the public and private health implementers at all levels of the health system (national, province, districts, sub-districts, and health facilities). Furthermore, it was not clear from the DHIS if the data was for patients who were clinically or laboratory diagnosed or a combination of both. Further investigations are needed either through focus group discussions and/or individual interviews or both with implementers at all levels of the health system to understand factors influencing compliance with the regulations relating to notifiable medical conditions.

Data Availability

The data underlying the results presented in the study are available on request from the National Department of Health (27 12 395 8096) and National Health Laboratory Health Services (27 11 386 7064).

CONFLICTS OF INTEREST

The authors declare that the study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

FINANCIAL SUPPORT

This work was supported by the University of KwaZulu-Natal College of Health Sciences PhD Scholarship (student number 216073797).

ACKNOWLEDGMENTS

We thank the National Department of Health, NHLS, NICD for providing schistosomiasis data. We are appreciative of the support with health facility location data from Silindile Gagai and other staff at BRIGHT Research in KwaZulu-Natal, South Africa.

REFERENCES

  1. 1.↵
    Aula OP, McManus DP, Jones MK, Gordon CA. Schistosomiasis with a focus on Africa. Vol. 6, Tropical Medicine and Infectious Disease. 2021. p. 1–40.
    OpenUrl
  2. 2.
    van Bogaert L. Case of invasive adenocarcinoma of the cervix in a human immunodeficiency virus and schistosome co-infected patient. South African J Gynaecol Oncol. 2014;6(1):5–6.
    OpenUrl
  3. 3.
    Pinto SZ, Friedman R, Van Den Berg EJ. A case of paediatric bladder bilharzioma in Johannesburg, South Africa. Clin Case Reports. 2019;7(10):1890–4.
    OpenUrl
  4. 4.↵
    Toller A, Scopin AC, Apfel V, Prigenzi KC, Tso FK, Focchi GR, et al. An interesting finding in the uterine cervix: Schistosoma hematobium calcified eggs. Autops Case Rep [Internet]. 2015/10/21. 2015;5(2):41–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26484333
    OpenUrl
  5. 5.
    van Bogaert L-JJ. Biopsy-diagnosed female genital schistosomiasis in rural Limpopo, South Africa. Int J Gynaecol Obstet [Internet]. 2011 Oct [cited 2013 Jan 15];115(1):75–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21767837
    OpenUrl
  6. 6.↵
    Christinet V, Lazdins-Helds JK, Stothard JR, Reinhard-Rupp J. Female genital schistosomiasis (FGS): from case reports to a call for concerted action against this neglected gynaecological disease. Int J Parasitol. 2016 Jun 1;46(7):395–404.
    OpenUrlCrossRefPubMed
  7. 7.
    Yirenya-Tawiah D, Amoah C, Apea-Kubi KA, Dade M, Ackumey M, Annang T, et al. A survey of female genital schistosomiasis of the lower reproductive tract in the volta basin of ghana. Ghana Med J [Internet]. 2011/05/17. 2011;45(1):16–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21572820
    OpenUrl
  8. 8.
    UNAIDS, World Health Organization. No more neglect. Female genital schistosomiasis and HIV. Integrating reproductive health interventions to improve women’s lives [Internet]. Geneva, Switzerland; 2019 [cited 2020 Mar 12]. Available from: https://www.unaids.org/sites/default/files/media_asset/female_genital_schistosomiasis_and_hiv_en.pdf
  9. 9.
    Randrianasolo BS, Jourdan PM, Ravoniarimbinina P, Ramarokoto CE, Rakotomanana F, Ravaoalimalala VE, et al. Gynecological manifestations, histopathological findings, and schistosoma-specific polymerase chain reaction results among women with Schistosoma haematobium infection: A cross-sectional study in Madagascar. J Infect Dis. 2015;212(2):1–11.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Ekpo UF, Odeyemi OM, Sam-Wobo SO, Onunkwor OB, Mogaji HO, Oluwole AS, et al. Female genital schistosomiasis (FGS) in Ogun State, Nigeria: a pilot survey on genital symptoms and clinical findings. Parasitol Open. 2017;3.
  11. 11.↵
    World Health Organisation. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030. Geneva, Switzerland: World Health Organisation; 2020. 1–196 p.
  12. 12.↵
    World Health Organization. WHO guideline on control and elimination of human schistosomiasis [Internet]. 2022. 142 p. Available from: https://www.who.int/publications/i/item/9789240041608?msclkid=66e125e4aa9911eca97802b2699b0852
  13. 13.↵
    Kjetland EF, Mduluza T, Ndhlovu PD, Gomo E, Gwanzura L, Midzi N, et al. Genital schistosomiasis in women: a clinical 12-month in vivo study following treatment with praziquantel. Trans R Soc Trop Med Hyg [Internet]. 2006;100(8):740–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16406034
    OpenUrl
  14. 14.
    Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis [Internet]. 2009/08/27. 2009;3(8):e412. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19707588
    OpenUrl
  15. 15.
    Tchuem Tchuenté LA, Rollinson D, Stothard JR, Molyneux D. Moving from control to elimination of schistosomiasis in sub-Saharan Africa: Time to change and adapt strategies. Infect Dis Poverty. 2017;6(1):1–14.
    OpenUrlPubMed
  16. 16.↵
    Bergquist R, Zhou XN, Rollinson D, Reinhard-Rupp J, Klohe K. Elimination of schistosomiasis: The tools required. Infect Dis Poverty. 2017;6(1):1–9.
    OpenUrlPubMed
  17. 17.↵
    Kjetland EF, Ndhlovu PD, Kurewa EN, Midzi N, Gomo E, Mduluza T, et al. Prevention of gynecologic contact bleeding and genital sandy patches by childhood anti-schistosomal treatment. Am J Trop Med Hyg [Internet]. 2008/07/09. 2008 Jul;79(1):79–83. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18606767
    OpenUrl
  18. 18.↵
    Kjetland EF, Gwanzura F, Ndhlovu PD, Mduluza T, Gomo E, Mason PR, et al. Simple clinical manifestations of genital Schistosoma haematobium infection in rural Zimbabwean women. Am J Trop Med Hyg [Internet]. 2005 Mar;72(3):311–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15772328
    OpenUrl
  19. 19.↵
    Mbabazi PS, Vwalika B, Randrianasolo BS, Roald B, Ledzinski D, Olowookorun F, et al. World Health Organisation Female genital schistosomiasis. A pocket atlas for clinical health-care professionals [Internet]. Vol. 2015, WHO/HTM/NTD/2015.4. Geneva: WHO; 2015. 1–49 p. Available from: http://apps.who.int/iris/bitstream/10665/180863/1/9789241509299_eng.pdf
  20. 20.↵
    Appleton CC, Naidoo I. Why did schistosomiasis disappear from the southern part of the Eastern Cape? S Afr J Sci [Internet]. 2012 Jan 9;108(1/2):1–11. Available from: http://www.sajs.co.za/index.php/SAJS/article/view/411
    OpenUrl
  21. 21.↵
    Torres-Vitolas CA, Dhanani N, Fleming FM. Factors affecting the uptake of preventive chemotherapy treatment for schistosomiasis in sub-saharan africa: A systematic review [Internet]. Vol. 15, PLoS Neglected Tropical Diseases. 2021. 1–33 p. Available from: doi:10.1371/journal.pntd.0009017
    OpenUrlCrossRef
  22. 22.↵
    de Boni L, Msimang V, de Voux A, Frean J. Trends in the prevalence of microscopicallyconfirmed schistosomiasis in the South African public health sector, 2011–2018. PLoS Negl Trop Dis [Internet]. 2021;15(9):2011–8. Available from: doi:10.1371/journal.pntd.0009669
    OpenUrlCrossRef
  23. 23.↵
    Appleton CC, Kvalsvig JD. A school-based helminth control programme successfully implemented in KwaZulu-Natal. South African J Epidemiol Infect [Internet]. 2006;21(2):55–67. Available from: http://www.sajei.co.za/index.php/SAJEI/article/view/42/38
    OpenUrl
  24. 24.↵
    van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop [Internet]. 2003;86(2–3):125–39. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12745133
    OpenUrl
  25. 25.↵
    Molvik M, Helland E, Zulu SG, Kleppa E, Lillebo K, Gundersen SG, et al. Co-infection with Schistosoma haematobium and soil-transmitted helminths in rural South Africa. S Afr J Sci. 2017;113(3–4):1–6.
    OpenUrl
  26. 26.
    Hegertun IEA, Sulheim Gundersen KM, Kleppa E, Zulu SG, Gundersen SG, Taylor M, et al. S. haematobium as a common cause of genital morbidity in girls: A cross-sectional study of children in South Africa. PLoS Negl Trop Dis. 2013;7(3):e2104.(1-8).
    OpenUrlCrossRefPubMed
  27. 27.
    Zulu SG, Kjetland EF, Gundersen SG, Taylor M. Prevalence and intensity of neglected tropical diseases (schistosomiasis and soil-transmitted helminths) amongst rural female pupils in Ugu district, KwaZulu-Natal, South Africa. South African J Infect Dis [Internet]. 2020 [cited 2020 Jun 16];35(1):1–7. Available from: https://sajid.co.za/index.php/sajid/article/view/123/288
    OpenUrl
  28. 28.↵
    Christensen EE, Taylor M, Zulu SG, Lillebo K, Gundersen SG, Holmen S, et al. Seasonal variations in Schistosoma haematobium egg excretion in school-age girls in rural Kwazulu-Natal province, South Africa. South African Med J. 2018;108(4):352–5.
    OpenUrl
  29. 29.↵
    National Department of Health. Regular treatment of school-going childen for soil-transmitted helminth infections and Bilharzia: Policy and implementation guidelines. South Africa: The South African National Department of Health; 2008 p. 38.
  30. 30.↵
    Livingston M, Pillay P, Zulu SG, Sandvik L, Kvalsvig JD, Gagai S, et al. Mapping Schistosoma haematobium for novel interventions against Female Genital Schistosomiasis and associated HIV risk in KwaZulu-Natal, South Africa. Am J Trop Med Hyg. 2021;104(6):2055–2064.
    OpenUrlPubMed
  31. 31.↵
    Feldmeier H, Poggensee G, Krantz I. A synoptic inventory of needs for research on women and tropical parasitic diseases. II. Gender-related biases in the diagnosis and morbidity assessment of schistosomiasis in women. Acta Trop [Internet]. 1993/11/01. 1993 Nov;55(3):139–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7903838
    OpenUrl
  32. 32.↵
    National Department of Health. Standard Treatment Guidelines And Essential Medicines List for South Africa: Primary Health Care Level [Internet]. 7th ed. Pretoria, South Africa: The South African National Department of Health; 2020 p. 1–561. Available from: https://www.knowledgehub.org.za/e-library
  33. 33.↵
    Nemungadi TG, Furumele TE, Gugerty MK, Djirmay AG, Naidoo S, Kjetland EF. Establishing and Integrating a Female Genital Schistosomiasis Control Programme into the Existing Health Care System. Trop Med Infect Dis 2022, Vol 7, Page 382 [Internet]. 2022 Nov 16 [cited 2022 Nov 21];7(11):382. Available from: https://www.mdpi.com/2414-6366/7/11/382/htm
    OpenUrl
  34. 34.↵
    Department of Health. Regulations relating to the surveillance and the control of notifiable medical conditions [Internet]. Government Gazette South Africa; 2017 p. 1–32. Available from: https://www.nicd.ac.za/wp-content/uploads/2017/12/41330_15-12_Health-compressed.pdf
  35. 35.↵
    National Department of Health. South Africa National Master Plan for the Elimination of Neglected Tropical Diseases. 2019 [cited 2024 Jan 30]; Available from: https://espen.afro.who.int/system/files/content/resources/South Africa NTD Master Plan v1.3.pdf
  36. 36.
    National Department of Health. DHIS [Internet]. [cited 2022 May 17]. Available from: https://za.dhis.dhmis.org/dhis-web-commons/security/login.action
  37. 37.
    Berge ST, Kabatereine NB, Gundersen SG, Taylor M, Kvalsvig JD, Mkhize-Kwitshana Z, et al. Generic praziquantel in South Africa: The necessity for policy change to avail cheap, safe and efficacious schistosomiasis drugs to the poor, rural population. South Afr J Epidemiol Infect [Internet]. 2011 [cited 2013 Jan 26];26(1):22–5. Available from: http://sajei.co.za/index.php/SAJEI/article/view/302
    OpenUrl
  38. 38.
    National Department of Health. Schistosomiasis and soil-transmitted helminths mapping findings. Pretoria, South Africa; 2021.
  39. 39.
    National Institute for Communicable Diseases. Centre for Emerging Zoonotic and Parasitic Diseases [Internet]. [cited 2022 May 17]. Available from: https://www.nicd.ac.za/centres/centre-for-emerging-zoonotic-and-parasitic-diseases/
  40. 40.
    Galappaththi-Arachchige HN, Zulu SG, Kleppa E, Lillebo K, Qvigstad E, Ndhlovu P, et al. Reproductive health problems in rural South African young women: risk behaviour and risk factors. Reprod Heal [Internet]. 2018/08/17. 2018;15(138):1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30111335
    OpenUrl
  41. 41.
    Sommerfelt I, Ndhlovu P, Taylor M, Naidoo S, Pillay P, Haaland H, et al. Health professionals’ knowledge about female genital schistosomiasis. A qualitative investigation in a schistosomiasis endemic area in South Africa. SSM - Qual Res Heal [Internet]. 2023 Jun 1 [cited 2023 Jun 26];3:100292. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2667321523000768
    OpenUrl
  42. 42.
    National Department of Health. Elimination of Schistosomiasis and Soil Transmitted Helminths as Public Health Problems in South Africa. 2010. p. 1–48.
  43. 43.
    National Department of Health. Coordination Mechanism for Neglected Tropical Diseases. 2017 p. 1–31.
  44. 44.↵
    National Department of Health. Mpumalanga NTD school prevalence. 2018.
  45. 45.
    National Department of Health. Limpopo NTD school prevalence. 2016.
  46. 46.↵
    National Department of Health. KwaZulu-Natal NTD school prevalence. 2016.
  47. 47.↵
    University of Witwatersrand. Healthcare in South Africa: how inequity is contributing to inefficiency [Internet]. 2021 [cited 2022 May 19]. Available from: https://www.wits.ac.za/news/latest-news/opinion/2021/2021-07/healthcare-in-south-africa-how-inequity-is-contributing-to-inefficiency.html#:~:text=South Africa hasatwo,around 27%25;25 of the population.
Back to top
Posted October 22, 2024.
Download PDF
Data/Code
Email
INSTITUTIONALISING SCHISTOSOMIASIS SURVEILLANCE: BEST PRACTICES TO IMPROVE FEMALE GENITAL AND URINARY SCHISTOSOMIASIS CONTROL IN SOUTH AFRICA
Takalani Girly Nemungadi, Tsakani Furumele, Absalom Mwazha, Myra Taylor, Saloshni Naidoo, Eyrun F. Kjetland
medRxiv 2024.10.21.24315852; doi: https://doi.org/10.1101/2024.10.21.24315852
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area